Skip to main content
OpenTrials
Completed

NCT Number: NCT00620178

Atacand (Candesartan) Real Life Study

This study is a Swedish historical cohort study in patients prescribed Atacand or Cozaar for hypertension by selected primary care centres. Data will be extracted anonymously from electronic medical records. In addition, data regarding morbidity and mortality will be collected by merging the cohort with the following national registries: the Hospital Discharge Register (Slutenvårdsregistret), the Cause of Death Register and the Heart Intensive Care Admission (RIKS-HIA)

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension Cardiovascular Diseases Vascular Diseases

Age range

17 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site

Uppsala, Sweden

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Recorded blood pressure prior to therapy of > 140 and/or 90 mmHg
  • Diagnosed as hypertensive within 15 months
  • First prescription of Cozaar or Atacand between 1 January 1999 and 31 December 2007, inclusive

Exclusion criteria

  • Previous prescription within 15 months any drug from the ATC groups C02, C03, C07 - C09 inclusive

Treatment and study plan

Candesartan cilexetil

Drug

oral once daily dose

Other names: ATACAND

Losartan

Drug

once daily oral dose

Other names: COZAAR

Primary outcomes

  1. The primary efficacy objective is to investigate, on basis of 'first to event', the development of new cardiovascular diseases (CVD).

    Time frame: 1999 - 2007

Secondary outcomes

  1. Cardiovascular disease states and procedures in the background and over the entire observation period will be identified by use of ICD-9 and ICD-10 coding for diseases of the cardiovascular system. Specifically are death, acute cardiovascular events, new

    Time frame: 1999 - 2007

  2. Health care consumption will be assessed as contacts with health care providers, in-hospital time periods for cardiovascular disease states with associated therapeutic procedures, and times spent within various levels of care (e.g. ICU and general ward).

    Time frame: 1999 - 2007

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

A REtrospective Study on the Effects of cAndesartan vs. Losartan on Blood Pressure, Health Care Consumption and cardiovascuLar Events In a "Real-liFe" GP sEtting in Sweden

Acronym: Real Life

Important dates

Study start
2008
Primary completion
2009
Study completion
2009
First posted
Feb 21, 2008
Registry last updated
Dec 2, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.